July/August 2017

The distribution of infusible specialty medications comes with difficulties that must be addressed by pharmacies and payers.

Implementing a quality-improvement project that allows for education and interdisciplinary collaboration among pharmacists, cardiologists, and primary care providers can improve rates of amiodarone monitoring.

The perception and utilization of OTC medications among primary care providers for gastroesophageal reflux disease and chronic constipation shows a need for improved patient education on these medications.

Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.

Healthcare stakeholders must work with regulators and policy makers to reduce barriers that prevent the alignment of a drug’s value and price.